"","PMID","FullCitation"
"1","22915242","Abe H, Maeda D, Hino R, et al. (2012) ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 461(4):367-77"
"2","14520695","Adem C, Soderberg CL, Cunningham JM, et al. (2003) Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer 107(4):580-2"
"3","23887303","Allo G, Bernardini MQ, Wu RC, et al. (2014) ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 27(2):255-61"
"4","18465328","Alsner J, Jensen V, Kyndi M, et al. (2008) A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 47(4):600-7"
"5","16288292","Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455-64"
"6","26936308","Ameratunga M, McArthur G, Gan H, et al. (2016) Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma. J Clin Pharm Ther ePub Mar 2016"
"7","10213220","Anbazhagan R, Fujii H, Gabrielson E (1999) Microsatellite instability is uncommon in breast cancer. Clin Cancer Res 5(4):839-44"
"8","27091708","André F, Hurvitz S, Fasolo A, et al. (2016) Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol ePub Apr 2016"
"9","24742739","André F, O'Regan R, Ozguroglu M, et al. (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580-91"
"10","25482239","Ansell SM, Lesokhin AM, Borrello I, et al. (2014) PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med ePub Dec 2014"
"11","23586058","Apostolou P, Fostira F (2013) Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013:747318"
"12","22565002","Bachelot T, Bourgier C, Cropet C, et al. (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718-24"
"13","24623249","Bairwa NK, Saha A, Gochhait S, et al. (2014) Microsatellite instability: an indirect assay to detect defects in the cellular mismatch repair machinery. Methods Mol Biol 1105:497-509"
"14","27939400","Balar AV, Galsky MD, Rosenberg JE, et al. (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67-76"
"15","22722202","Banerji S, Cibulskis K, Rangel-Escareno C, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405-9"
"16","26541326","Baptista MZ, Sarian LO, Derchain SF, et al. (2015) Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol ePub Sep 2015"
"17","17947469","Barbareschi M, Buttitta F, Felicioni L, et al. (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13(20):6064-9"
"18","22744290","Barbareschi M, Cuorvo LV, Girlando S, et al. (2012) PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch 461(2):129-39"
"19","22149876","Baselga J, Campone M, Piccart M, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-9"
"20","19380449","Baselga J, Semiglazov V, van Dam P, et al. (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630-7"
"21","27893038","Basho RK, Gilcrease M, Murthy RK, et al. (2017) Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515"
"22","21635707","Bazarov AV, Yaswen P (2011) Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors. Breast Cancer Res 13(3):308"
"23","24362951","Beck JT, Hortobagyi GN, Campone M, et al. (2014) Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 143(3):459-67"
"24","7657393","Bellacosa A, de Feo D, Godwin AK, et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64(4):280-5"
"25","20460501","Benson DM, Bakan CE, Mishra A, et al. (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13):2286-94"
"26","25686104","Bitler BG, Aird KM, Garipov A, et al. (2015) Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21(3):231-8"
"27","20420947","Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073-2087.e3"
"28","9823339","Boland CR, Thibodeau SN, Hamilton SR, et al. (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248-57"
"29","26412456","Borghaei H, Paz-Ares L, Horn L, et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med ePub Sep 2015"
"30","23702729","Bosse T, ter Haar NT, Seeber LM, et al. (2013) Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 26(11):1525-35"
"31","27001570","Bouffet E, Larouche V, Campbell BB, et al. (2016) Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol ePub Mar 2016"
"32","26014290","Bougeard G, Renaux-Petel M, Flaman JM, et al. (2015) Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 33(21):2345-52"
"33","26028407","Brahmer J, Reckamp KL, Baas P, et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med ePub May 2015"
"34","21799033","Bridges KA, Hirai H, Buser CA, et al. (2011) MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 17(17):5638-48"
"35","23447401","Briggs S, Tomlinson I (2013) Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 230(2):148-53"
"36","19935675","Brown CJ, Lain S, Verma CS, et al. (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9(12):862-73"
"37","27499907","Budczies J, Bockmayr M, Denkert C, et al. (2015) Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res 1(4):225-38"
"38","22034109","Buerki N, Gautier L, Kovac M, et al. (2012) Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 51(1):83-91"
"39","22949682","Burke JE, Perisic O, Masson GR, et al. (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci USA 109(38):15259-64"
"40","17629517","Butte MJ, Keir ME, Phamduy TB, et al. (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111-22"
"41","23470564","Camp ER, Wang C, Little EC, et al. (2013) Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 20(4):222-8"
"42","22810696","Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330-7"
"43","23000897","Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70"
"44","25631445","Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576-82"
"45","22960745","Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-25"
"46","23636398","Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67-73"
"47","23444215","Catalanotti F, Solit DB, Pulitzer MP, et al. (2013) Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 19(8):2257-64"
"48","12217765","Ceccaroni M, Genuardi M, Legge F, et al. (2002) BRCA1-related malignancies in a family presenting with von Recklinghausen's disease. Gynecol Oncol 86(3):375-8"
"49","20581867","Chakrabarty A, Rexer BN, Wang SE, et al. (2010) H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29(37):5193-203"
"50","23221337","Chang T, Krisman K, Theobald EH, et al. (2013) Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest 123(1):335-9"
"51","24185513","Chan-On W, Nairismägi ML, Ong CK, et al. (2013) Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45(12):1474-8"
"52","25583476","Chen K, Yang D, Li X, et al. (2015) Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proc Natl Acad Sci USA ePub Jan 2015"
"53","24874471","Chen Y, McGee J, Chen X, et al. (2014) Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS ONE 9(5):e98293"
"54","1409633","Cheng JQ, Godwin AK, Bellacosa A, et al. (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89(19):9267-71"
"55","21519185","Chin YR, Toker A Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr 5(3):211-4"
"56","24925223","Chou A, Toon CW, Clarkson A, et al. (2014) Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol 45(8):1697-703"
"57","22997091","Christgen M, Noskowicz M, Schipper E, et al. (2013) Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer 52(1):69-80"
"58","18409144","Cicenas J The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23(1):1-9"
"59","26451490","Ciriello G, Gatza ML, Beck AH, et al. (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163(2):506-19"
"60","23171949","Craig DW, O'Shaughnessy JA, Kiefer JA, et al. (2013) Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 12(1):104-16"
"61","20530683","Dan S, Okamura M, Seki M, et al. (2010) Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res 70(12):4982-94"
"62","12615735","de Leeuw WJ, van Puijenbroek M, Tollenaar RA, et al. (2003) Correspondence re: A. Müller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res., 62: 1014-1019, 2002. Cancer Res 63(5):1148-9"
"63","22829094","Derenzini E, Lemoine M, Buglio D, et al. (2011) The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 1(12):e46"
"64","26627007","Dogruluk T, Tsang YH, Espitia M, et al. (2015) Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res 75(24):5341-54"
"65","26787751","Dolly S, Wagner AJ, Bendell JC, et al. (2016) Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res ePub Jan 2016"
"66","28029918","Dombi E, Baldwin A, Marcus LJ, et al. (2016) Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med 375(26):2550-2560"
"67","28039262","Dong ZY, Zhong WZ, Zhang XC, et al. (2016) Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res"
"68","23525077","Dulak AM, Stojanov P, Peng S, et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45(5):478-86"
"69","19629070","Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550-62"
"70","23036231","Evans DG, Huson SM, Birch JM (2012) Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res 2(1):17"
"71","26970723","Fehrenbacher L, Spira A, Ballinger M, et al. (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837-46"
"72","22245973","Fleming GF, Ma CX, Huo D, et al. (2012) Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136(2):355-63"
"73","23305873","Fohlin H, Pérez-Tenorio G, Fornander T, et al. (2013) Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. Eur J Cancer 49(6):1196-204"
"74","27179933","Fransson Å, Glaessgen D, Alfredsson J, et al. (2016) Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. J Ovarian Res 9(1):27"
"75","24608574","Fritsch C, Huang A, Chatenay-Rivauday C, et al. (2014) Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials. Mol Cancer Ther 13(5):1117-29"
"76","15637391","Garber JE, Offit K (2005) Hereditary cancer predisposition syndromes. J Clin Oncol 23(2):276-92"
"77","25891174","Garon EB, Rizvi NA, Hui R, et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med ePub Apr 2015"
"78","25392179","Gatalica Z, Snyder C, Maney T, et al. (2014) Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 23(12):2965-70"
"79","18347814","Geng L, Huang D, Liu J, et al. (2008) B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 134(9):1021-7"
"80","18294387","Ghebeh H, Barhoush E, Tulbah A, et al. (2008) FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 8:57"
"81","16611412","Ghebeh H, Mohammed S, Al-Omair A, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3):190-8"
"82","19204208","Gonzalez KD, Noltner KA, Buzin CH, et al. (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250-6"
"83","20628145","Green MR, Monti S, Rodig SJ, et al. (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268-77"
"84","27900363","Gröschel S, Bommer M, Hutter B, et al. (2016) Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud 2(6):a001180"
"85","23097632","Guan B, Gao M, Wu CH, et al. (2012) Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia 14(10):986-93"
"86","21900401","Guan B, Wang TL, Shih IeM (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71(21):6718-27"
"87","15588864","Güran S, Safali M (2005) A case of neurofibromatosis and breast cancer: loss of heterozygosity of NF1 in breast cancer. Cancer Genet Cytogenet 156(1):86-8"
"88","17376864","Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104(13):5569-74"
"89","17360651","Hamanishi J, Mandai M, Iwasaki M, et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360-5"
"90","18314908","Han W, Jung EM, Cho J, et al. (2008) DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 47(6):490-9"
"91","24839032","Haricharan S, Bainbridge MN, Scheet P, et al. (2014) Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat 146(1):211-20"
"92","21870995","Hasan A, Ghebeh H, Lehe C, et al. (2011) Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets 15(10):1211-25"
"93","1904223","Hattori S, Ohmi N, Maekawa M, et al. (1991) Antibody against neurofibromatosis type 1 gene product reacts with a triton-insoluble GTPase activating protein toward ras p21. Biochem Biophys Res Commun 177(1):83-9"
"94","24583393","Heitzer E, Tomlinson I (2014) Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev 24:107-13"
"95","25680375","Herbst RS, Gandara DR, Hirsch FR, et al. (2015) Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21(7):1514-24"
"96","25428504","Herbst RS, Soria JC, Kowanetz M, et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563-7"
"97","23875803","Hill VK, Gartner JJ, Samuels Y, et al. (2013) The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 14:257-79"
"98","20143437","Hino R, Kabashima K, Kato Y, et al. (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757-66"
"99","20107315","Hirai H, Arai T, Okada M, et al. (2010) MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 9(7):514-22"
"100","20571069","Hirai H, Sootome H, Nakatsuru Y, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956-67"
"101","21337521","Holland DG, Burleigh A, Git A, et al. (2011) ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3(3):167-80"
"102","22120714","Hon WC, Berndt A, Williams RL (2012) Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 31(32):3655-66"
"103","18317450","Horn S, Bergholz U, Jücker M, et al. (2008) Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 27(29):4096-106"
"104","25195947","Huang H, Lin M, Tseng L, et al. (2014) Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression. Histopathology ePub Sep 2014"
"105","24336158","Huang HN, Lin MC, Huang WC, et al. (2013) Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol ePub Dec 2013"
"106","22922871","Huang J, Deng Q, Wang Q, et al. (2012) Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 44(10):1117-21"
"107","26092818","Hurvitz SA, Andre F, Jiang Z, et al. (2015) Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16(7):816-29"
"108","25394778","Hussein YR, Weigelt B, Levine DA, et al. (2014) Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol ePub Nov 2014"
"109","15930273","Ikenoue T, Kanai F, Hikiba Y, et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562-7"
"110","22805291","Infante JR, Fecher LA, Falchook GS, et al. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13(8):773-81"
"111","23583440","Infante JR, Papadopoulos KP, Bendell JC, et al. (2013) A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer 49(9):2077-85"
"112","12218188","Iwai Y, Ishida M, Tanaka Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-7"
"113","24931142","Janku F, Kaseb AO, Tsimberidou AM, et al. (2014) Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget 5(10):3012-22"
"114","21216929","Janku F, Tsimberidou AM, Garrido-Laguna I, et al. (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65"
"115","22271473","Janku F, Wheler JJ, Westin SN, et al. (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82"
"116","23221341","Jessen WJ, Miller SJ, Jousma E, et al. (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123(1):340-7"
"117","20027112","Jett K, Friedman JM (2010) Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12(1):1-11"
"118","24293293","Jiao Y, Yonescu R, Offerhaus GJ, et al. (2014) Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 232(4):428-35"
"119","18410249","Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77:557-82"
"120","18164202","Johannessen CM, Johnson BW, Williams SM, et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18(1):56-62"
"121","15937108","Johannessen CM, Reczek EE, James MF, et al. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102(24):8573-8"
"122","27683556","Johanns TM, Miller CA, Dorward IG, et al. (2016) Immunogenomics of Hypermutated Glioblastoma: a Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov ePub Sep 2016"
"123","27671167","Johnson DB, Frampton GM, Rioth MJ, et al. (2016) Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res ePub Sep 2016"
"124","22009941","Jones S, Li M, Parsons DW, et al. (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 33(1):100-3"
"125","20826764","Jones S, Wang TL, Shih IeM, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330(6001):228-31"
"126","25907661","Jousma E, Rizvi TA, Wu J, et al. (2015) Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer 62(10):1709-16"
"127","19671852","Kalinsky K, Jacks LM, Heguy A, et al. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16):5049-59"
"128","20978130","Kamada R, Nomura T, Anderson CW, et al. (2011) Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem 286(1):252-8"
"129","22928966","Kamat N, Khidhir MA, Jaloudi M, et al. (2012) High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study. BMC Cancer 12:373"
"130","23011637","Kang D, Cho HS, Toyokawa G, et al. (2013) The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer 52(2):126-39"
"131","15647370","Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102(3):802-7"
"132","22101352","Katagiri A, Nakayama K, Rahman MT, et al. (2012) Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25(2):282-8"
"133","19633047","Kataoka Y, Mukohara T, Shimada H, et al. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21(2):255-62"
"134","12826609","Kato S, Han SY, Liu W, et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100(14):8424-9"
"135","18173375","Keir ME, Butte MJ, Freeman GJ, et al. (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704"
"136","1918816","Kidd DJ (1991) Preparing illustrations for half-tone reproduction. 1952. J Audiov Media Med 14(1):35-8"
"137","26552009","Kim KH, Kim W, Howard TP, et al. (2015) SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med 21(12):1491-6"
"138","16682010","Kim SM, Kee HJ, Eom GH, et al. (2006) Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity. Biochem Biophys Res Commun 345(1):318-23"
"139","25240597","Kim SS, Rait A, Kim E, et al. (2015) A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 11(2):301-11"
"140","9006316","Kleihues P, Schäuble B, zur Hausen A, et al. (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150(1):1-13"
"141","26337942","Kocarnik JM, Shiovitz S, Phipps AI (2015) Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 3(4):269-76"
"142","26214590","Krauthammer M, Kong Y, Bacchiocchi A, et al. (2015) Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 47(9):996-1002"
"143","26140250","Kroemer G, Galluzzi L, Zitvogel L, et al. (2015) Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology 4(7):e1058597"
"144","25949894","Lal N, Beggs AD, Willcox BE, et al. (2015) An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. Oncoimmunology 4(3):e976052"
"145","12672316","Lalloo F, Varley J, Ellis D, et al. (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361(9363):1101-2"
"146","25265494","Larkin J, Ascierto PA, Dréno B, et al. (2014) Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med ePub Sep 2014"
"147","26027431","Larkin J, Chiarion-Sileni V, Gonzalez R, et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(1):23-34"
"148","2103068","Laurenti R, Buchalla CM, de Lolio CA, et al. (1990) [Mortality among women in reproductive age in the municipality of São Paulo, Brazil, 1986. II. Deaths by maternal causes]. Rev Saude Publica 24(6):468-72"
"149","26028255","Le DT, Uram JN, Wang H, et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med ePub May 2015"
"150","28471727","Lee JM, Cimino-Mathews A, Peer CJ, et al. (2017) Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. J Clin Oncol 35(19):2193-2202"
"151","22965953","Lehmann S, Bykov VJ, Ali D, et al. (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633-9"
"152","22767668","Leijen S, Middleton MR, Tresca P, et al. (2012) Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 18(17):4794-805"
"153","27601554","Leijen S, van Geel RM, Pavlick AC, et al. (2016) Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol ePub Sep 2016"
"154","29333945","Li B, Tao W, Shao-Hua Z, et al. (2018) Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy. Cancer Biol Ther :1-4"
"155","26859683","Lim SM, Park HS, Kim S, et al. (2016) Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget ePub Feb 2016"
"156","9679957","Liu AX, Testa JR, Hamilton TC, et al. (1998) AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 58(14):2973-7"
"157","17363736","Liu J, Hamrouni A, Wolowiec D, et al. (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110(1):296-304"
"158","23301057","Loi S, Michiels S, Baselga J, et al. (2013) PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS ONE 8(1):e53292"
"159","18486325","Loos M, Giese NA, Kleeff J, et al. (2008) Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 268(1):98-109"
"160","23619167","Lui VW, Hedberg ML, Li H, et al. (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761-9"
"161","22446188","Ma CX, Cai S, Li S, et al. (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122(4):1541-52"
"162","25017610","Ma F, Bi L, Yang G, et al. (2014) ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer. Oncol Rep 32(3):1071-7"
"163","23165953","Madanikia SA, Bergner A, Ye X, et al. (2012) Increased risk of breast cancer in women with NF1. Am J Med Genet A 158A(12):3056-60"
"164","23171796","Maertens O, Johnson B, Hollstein P, et al. (2013) Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 3(3):338-49"
"165","24913553","Malone CF, Fromm JA, Maertens O, et al. (2014) Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov 4(9):1062-73"
"166","21892209","Mamo A, Cavallone L, Tuzmen S, et al. (2012) An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31(16):2090-100"
"167","27269937","Massard C, Gordon MS, Sharma S, et al. (2016) Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 34(26):3119-25"
"168","27126994","Mayer IA, Abramson VG, Formisano L, et al. (2017) A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res 23(1):26-34"
"169","27159395","Mehnert JM, Panda A, Zhong H, et al. (2016) Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126(6):2334-40"
"170","22422409","Meric-Bernstam F, Akcakanat A, Chen H, et al. (2012) PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777-89"
"171","24764583","Mittendorf EA, Philips AV, Meric-Bernstam F, et al. (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70"
"172","26086967","Mohell N, Alfredsson J, Fransson Å, et al. (2015) APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis 6:e1794"
"173","8628317","Morcos P, Thapar N, Tusneem N, et al. (1996) Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Mol Cell Biol 16(5):2496-503"
"174","21664949","Morishita M, di Luccio E (2011) Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta 1816(2):158-63"
"175","22927482","Moroney J, Fu S, Moulder S, et al. (2012) Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 18(20):5796-805"
"176","21890452","Moroney JW, Schlumbrecht MP, Helgason T, et al. (2011) A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17(21):6840-6"
"177","26406148","Motzer RJ, Escudier B, McDermott DF, et al. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med ePub Sep 2015"
"178","25878190","Moulder S, Helgason T, Janku F, et al. (2015) Inhibition of the Phosphoinositide 3-kinase Pathway for the Treatment of Patients with Metastatic Metaplastic Breast Cancer. Ann Oncol ePub Apr 2015"
"179","28183140","Moynahan ME, Chen D, He W, et al. (2017) Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2. Br J Cancer 116(6):726-730"
"180","24842267","Muenst S, Schaerli AR, Gao F, et al. (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 146(1):15-24"
"181","27138582","Nanda R, Chow LQ, Dees EC, et al. (2016) Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol ePub May 2016"
"182","11219776","Nichols KE, Malkin D, Garber JE, et al. (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10(2):83-7"
"183","24576830","Nissan MH, Pratilas CA, Jones AM, et al. (2014) Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 74(8):2340-50"
"184","17404099","Nomi T, Sho M, Akahori T, et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13(7):2151-7"
"185","18829572","Oda K, Okada J, Timmerman L, et al. (2008) PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68(19):8127-36"
"186","16489069","Olivier M, Langerød A, Carrieri P, et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12(4):1157-67"
"187","25504633","Osman AA, Monroe MM, Ortega Alves MV, et al. (2015) Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther 14(2):608-19"
"188","27105424","Park HS, Lim SM, Kim S, et al. (2016) Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. PLoS ONE 11(4):e0154133"
"189","27489289","Parsons HA, Beaver JA, Cimino-Mathews A, et al. (2016) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer. Clin Cancer Res ePub Aug 2016"
"190","22240541","Patil S, Chamberlain RS (2012) Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 17(1):101-16"
"191","15528785","Pawlik TM, Raut CP, Rodriguez-Bigas MA (2004) Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers 20(4-5):199-206"
"192","12379884","Pfeifer GP, Denissenko MF, Olivier M, et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21(48):7435-51"
"193","15748635","Pfeifer GP, You YH, Besaratinia A (2005) Mutations induced by ultraviolet light. Mutat Res 571(1-2):19-31"
"194","25231953","Piccart M, Hortobagyi GN, Campone M, et al. (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol ePub Sep 2014"
"195","27357628","Pirollo KF, Nemunaitis J, Leung PK, et al. (2016) Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol Ther 24(9):1697-706"
"196","25891304","Postow MA, Chesney J, Pavlick AC, et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006-17"
"197","21389100","Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. (2011) MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17(9):2799-806"
"198","23592373","Ramirez-Ardila DE, Helmijr JC, Look MP, et al. (2013) Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 139(1):39-49"
"199","24156016","Reynisdottir I, Arason A, Einarsdottir BO, et al. (2013) High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. Cancer Med 2(4):437-46"
"200","15483017","Rinehart J, Adjei AA, Lorusso PM, et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22(22):4456-62"
"201","8646682","Risinger JI, Barrett JC, Watson P, et al. (1996) Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77(9):1836-43"
"202","22729224","Rivière JB, Mirzaa GM, O'Roak BJ, et al. (2012) De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44(8):934-40"
"203","25765070","Rizvi NA, Hellmann MD, Snyder A, et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124-8"
"204","25704439","Rizvi NA, Mazières J, Planchard D, et al. (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol ePub Feb 2015"
"205","25399552","Robert C, Long GV, Brady B, et al. (2014) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med ePub Nov 2014"
"206","25568919","Roberts SA, Gordenin DA (2014) Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 14(12):786-800"
"207","11986249","Rosati R, La Starza R, Veronese A, et al. (2002) NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99(10):3857-60"
"208","26952546","Rosenberg JE, Hoffman-Censits J, Powles T, et al. (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909-20"
"209","24563076","Ross JS, Wang K, Gay L, et al. (2014) New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19(3):235-42"
"210","22430209","Ross RL, Askham JM, Knowles MA (2013) PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 32(6):768-76"
"211","21266528","Rudd ML, Price JC, Fogoros S, et al. (2011) A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 17(6):1331-40"
"212","29559561","Rugo HS, Delord JP, Im SA, et al. (2018) Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor‒Positive/Human Epidermal Growth Factor Receptor 2‒Negative Advanced Breast Cancer. Clin Cancer Res"
"213","19466510","Salemis NS, Nakos G, Sambaziotis D, et al. (2010) Breast cancer associated with type 1 neurofibromatosis. Breast Cancer 17(4):306-9"
"214","24979463","Samartzis EP, Gutsche K, Dedes KJ, et al. (2014) Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget ePub Jun 2014"
"215","15950905","Samuels Y, Diaz LA, Schmidt-Kittler O, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561-73"
"216","27486176","Santin AD, Bellone S, Buza N, et al. (2016) Regression of chemotherapy-resistant Polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res ePub Aug 2016"
"217","22363436","Scrima M, De Marco C, Fabiani F, et al. (2012) Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS ONE 7(2):e30427"
"218","22573716","See WL, Tan IL, Mukherjee J, et al. (2012) Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res 72(13):3350-9"
"219","19123071","Shanley S, Fung C, Milliken J, et al. (2009) Breast cancer immunohistochemistry can be useful in triage of some HNPCC families. Fam Cancer 8(3):251-5"
"220","25025450","Shi M, Roemer MG, Chapuy B, et al. (2014) Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain. Am J Surg Pathol ePub Jul 2014"
"221","19394761","Shibata T, Kokubu A, Tsuta K, et al. (2009) Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 283(2):203-11"
"222","24684785","Singh J, Novik Y, Stein S, et al. (2014) Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 16(2):R32"
"223","21328542","Sircoulomb F, Nicolas N, Ferrari A, et al. (2011) ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 3(3):153-66"
"224","21317240","Slorach EM, Chou J, Werb Z (2011) Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev 25(5):471-84"
"225","25409260","Snyder A, Makarov V, Merghoub T, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189-99"
"226","23355100","Sorrell AD, Espenschied CR, Culver JO, et al. (2013) Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions. Mol Diagn Ther 17(1):31-47"
"227","22722201","Stephens PJ, Tarpey PS, Davies H, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400-4"
"228","23318448","Streppel MM, Lata S, DelaBastide M, et al. (2014) Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 33(3):347-57"
"229","25982012","Subbiah V, Berry J, Roxas M, et al. (2015) Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89(1):76-9"
"230","25466466","Suzuki S, Kurabe N, Ohnishi I, et al. (2015) NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. Pathol Res Pract 211(5):404-8"
"231","19380029","Taketani T, Taki T, Nakamura H, et al. (2009) NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 190(2):108-12"
"232","24714771","Taube JM, Klein A, Brahmer JR, et al. (2014) Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res ePub Apr 2014"
"233","10780879","Taubert H, Meye A, Würl P (1998) Soft tissue sarcomas and p53 mutations. Mol Med 4(6):365-72"
"234","24476821","The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature ePub Jan 2014"
"235","25079317","The Cancer Genome Atlas Research Network, Analysis Working Group: Dana-Farber Cancer Institute, Institute for Systems Biology, et al. (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature ePub Jul 2014"
"236","8646743","Thompson FH, Nelson MA, Trent JM, et al. (1996) Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet 87(1):55-62"
"237","15569934","Thompson RH, Gillett MD, Cheville JC, et al. (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101(49):17174-9"
"238","16585157","Thompson RH, Kuntz SM, Leibovich BC, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381-5"
"239","25344362","Tolcher AW, Bendell JC, Papadopoulos KP, et al. (2014) A Phase IB Trial of the Oral MEK Inhibitor Trametinib (GSK1120212) in Combination With Everolimus in Patients With Advanced Solid Tumors. Ann Oncol ePub Oct 2014"
"240","22658127","Topalian SL, Hodi FS, Brahmer JR, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-54"
"241","24590637","Topalian SL, Sznol M, McDermott DF, et al. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020-30"
"242","24497532","Twa DD, Chan FC, Ben-Neriah S, et al. (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123(13):2062-5"
"243","8544190","Upadhyaya M, Maynard J, Osborn M, et al. (1995) Characterisation of germline mutations in the neurofibromatosis type 1 (NF1) gene. J Med Genet 32(9):706-10"
"244","26359337","Van Allen EM, Miao D, Schilling B, et al. (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207-11"
"245","23359294","Végran F, Rebucci M, Chevrier S, et al. (2013) Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS ONE 8(1):e55103"
"246","23480528","Verstovsek S, Mesa RA, Gotlib J, et al. (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508-16"
"247","12094235","Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489-501"
"248","25002028","Vora SR, Juric D, Kim N, et al. (2014) CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors. Cancer Cell 26(1):136-49"
"249","22851646","Wallace MD, Pfefferle AD, Shen L, et al. (2012) Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics 192(2):385-96"
"250","20215533","Walsh MD, Buchanan DD, Cummings MC, et al. (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16(7):2214-24"
"251","16551709","Walsh T, Casadei S, Coats KH, et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379-88"
"252","22808142","Wang DD, Chen YB, Pan K, et al. (2012) Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS ONE 7(7):e40364"
"253","22037554","Wang K, Kan J, Yuen ST, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43(12):1219-23"
"254","21676217","Wang L, Zhang Q, Zhang J, et al. (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:248"
"255","22965642","Wang X, Levin AM, Smolinski SE, et al. (2012) Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 158A(12):3061-4"
"256","25795410","Weber JS, D'Angelo SP, Minor D, et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375-84"
"257","25561809","Wei XL, Wang DS, Xi SY, et al. (2014) Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol 20(48):18404-12"
"258","25314964","Weiss B, Widemann BC, Wolters P, et al. (2014) Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro-oncology ePub Oct 2014"
"259","24912489","Wheler JJ, Moulder SL, Naing A, et al. (2014) Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget 5(10):3029-38"
"260","23288408","Whittaker SR, Theurillat JP, Van Allen E, et al. (2013) A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 3(3):350-62"
"261","24559118","Wiegand KC, Hennessy BT, Leung S, et al. (2014) A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 14:120"
"262","20942669","Wiegand KC, Shah SP, Al-Agha OM, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532-43"
"263","24767857","Wiegand KC, Sy K, Kalloger SE, et al. (2014) ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum Pathol 45(6):1258-68"
"264","19117870","Williams VC, Lucas J, Babcock MA, et al. (2009) Neurofibromatosis type 1 revisited. Pediatrics 123(1):124-33"
"265","23233719","Wolff AC, Lazar AA, Bondarenko I, et al. (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31(2):195-202"
"266","19915146","Wu H, Shekar SC, Flinn RJ, et al. (2009) Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci USA 106(48):20258-63"
"267","21666724","Wu J, Liu S, Liu G, et al. (2012) Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene 31(3):333-41"
"268","24618703","Wu RC, Wang TL, Shih IeM (2014) The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 15(6):655-64"
"269","24833095","Xie C, Fu L, Han Y, et al. (2014) Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma. Tumour Biol 35(8):7921-7"
"270","18171600","Xing H, Weng D, Chen G, et al. (2008) Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 261(1):108-19"
"271","12489850","Xu L, Huang CC, Huang W, et al. (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1(5):337-46"
"272","11713371","Xu L, Tang WH, Huang CC, et al. (2001) Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7(10):723-34"
"273","24293408","Yan HB, Wang XF, Zhang Q, et al. (2014) Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis 35(4):867-76"
"274","24481460","Yang G, Ma F, Zhong M, et al. (2014) ZNF703 acts as an oncogene that promotes progression in gastric cancer. Oncol Rep 31(4):1877-82"
"275","25311944","Ye J, Zhou Y, Weiser MR, et al. (2014) Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. Hum Pathol 45(12):2430-6"
"276","8137273","Yee CJ, Roodi N, Verrier CS, et al. (1994) Microsatellite instability and loss of heterozygosity in breast cancer. Cancer Res 54(7):1641-4"
"277","24459582","Yokoyama Y, Matsushita Y, Shigeto T, et al. (2014) Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol 25(1):58-63"
"278","21081928","You JF, Buhard O, Ligtenberg MJ, et al. (2010) Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer 103(12):1840-5"
"279","29209571","Yuan Y, Kos FJ, He TF, et al. (2017) Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. Oncoimmunology 6(12):e1363138"
"280","25892646","Zaman K, Winterhalder R, Mamot C, et al. (2015) Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 51(10):1212-20"
"281","22484628","Zang ZJ, Cutcutache I, Poon SL, et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44(5):570-4"
"282","23991038","Zhang X, Mu X, Huang O, et al. (2013) Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS ONE 8(8):e72053"
"283","21889920","Zhang X, Zhang Y, Yang Y, et al. (2012) Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 36(3):288-93"
"284","24430365","Zhao J, Liu C, Zhao Z (2014) ARID1A: a potential prognostic factor for breast cancer. Tumour Biol ePub Jan 2014"
"285","18794883","Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27(41):5486-96"
"286","24947927","Zimmer L, Barlesi F, Martinez-Garcia M, et al. (2014) Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS-RAF Mutations. Clin Cancer Res 20(16):4251-61"
